NASDAQ · CING
Cingulate Inc.
$5.19-$0.06 (-1.14%)
Cingulate Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.35% below the high.
Loading market information…
NASDAQ · PASG · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Passage Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.4% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Passage Bio, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$2.43. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Passage Bio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$4.00-1,677.78% vs estimate |
| $0.00 |
| Q3 2024 | Nov 13, 2024 | -$6.20-34.78% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.19-$0.06 (-1.14%)
Cingulate Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.35% below the high.
$2.54-$0.07 (-2.68%)
Enlivex Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 99.42% below the high.
$0.89-$0.06 (-6.32%)
Allarity Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.63% below the high.
$0.90-$0.03 (-3.68%)
CytoMed Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 70.95% below the high.
$1.01-$0.05 (-4.72%)
Lisata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.08% below the high.
$4.40+$0.45 (+11.39%)
CollPlant Biotechnologies Ltd.’s quoted price sits in the lower half of its reported 52-week range, 80.79% below the high.
$1.19+$0.05 (+4.39%)
MetaVia Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.99% below the high.
$1.04-$0.04 (-3.26%)
NuCana plc’s quoted price sits in the lower half of its reported 52-week range, 77.14% below the high.
